• Sarilumab for hospitalized COVID-19 infections
• Cytokine storm syndrome • Phase 2/3 RCT
• Phase 2: Sarilumab in hospitalized patients regardless of disease severity vs. placebo
• Primary outcome of % change in CRP in patients with serum IL-6 > upper limit normal
• Phase 3 Cohort 1: Sarilumab in hospitalized critical infection receiving mechanical ventilation vs. placebo
• Cohort 2: Sarilumab in hospitalized infection receiving mechanical ventilation vs. placebo
•  N = 1912
• Primary outcome of at least 1 point improvement on 7 point clinical scale • Phase 2: Low dose sarilumab i.v.
• Phase 2: Mid-dose sarilumab i.v.
• Phase 3 Cohort 1: Low dose sarilumab i.v.
• Phase 3 Cohort 1: Mid-dose sarilumab i.v.
• Phase 3 Cohort 2: High dose sarilumab i.v.
• Placebo given to match sarilumab administration (NCT04315298, 2020)